| [1] | COVARRUBIAS A J, PERRONE R, GROZIO A, et al. NAD+ metabolism and its roles in cellular processes during ageing[J]. Nat Rev Mol Cell Biol, 2021, 22(2):119-141. doi: 10.1038/s41580-020-00313-x |
| [2] | WANG P, MIAO C Y. NAMPT as a therapeutic target against stroke[J]. Trends Pharmacol Sci, 2015, 36(12):891-905. doi: 10.1016/j.tips.2015.08.012 |
| [3] | YOSHINO J, BAUR J A, IMAI S I. NAD+ intermediates: the biology and therapeutic potential of NMN and NR[J]. Cell Metab, 2018, 27(3):513-528. doi: 10.1016/j.cmet.2017.11.002 |
| [4] | YOSHINO J, MILLS K F, YOON M J, et al. Nicotinamide mononucleotide, a key NAD(+)intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice[J]. Cell Metab, 2011, 14(4):528-536. doi: 10.1016/j.cmet.2011.08.014 |
| [5] | WANG S N, MIAO C Y. Targeting NAMPT as a therapeutic strategy against stroke[J]. Stroke Vasc Neurol, 2019, 4(2):83-89. doi: 10.1136/svn-2018-000199 |
| [6] | YAGI M, DO Y, HIRAI H, et al. Improving lysosomal ferroptosis with NMN administration protects against heart failure[J]. Life Sci Alliance, 2023, 6(12):e202302116. doi: 10.26508/lsa.202302116 |
| [7] | DENG H Y, DING D, MA Y, et al. Nicotinamide mononucleotide: research process in cardiovascular diseases[J]. Int J Mol Sci, 2024, 25(17):9526. doi: 10.3390/ijms25179526 |
| [8] | SONG Q, ZHOU X F, XU K X, et al. The safety and antiaging effects of nicotinamide mononucleotide in human clinical trials: an update[J]. Adv Nutr, 2023, 14(6):1416-1435. doi: 10.1016/j.advnut.2023.08.008 |
| [9] | HUANG H. A multicentre, randomised, double blind, parallel design, placebo controlled study to evaluate the efficacy and safety of uthever(NMN supplement), an orally administered supplementation in middle aged and older adults[J]. Front Aging, 2022, 3:851698. doi: 10.3389/fragi.2022.851698 |
| [10] | YI L, MAIER A B, TAO R S, et al. The efficacy and safety of β-nicotinamide mononucleotide(NMN)supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial[J]. Geroscience, 2023, 45(1):29-43. doi: 10.1007/s11357-022-00705-1 |
| [11] | IGARASHI M, NAKAGAWA-NAGAHAMA Y, MIURA M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men[J]. NPJ Aging, 2022, 8(1):5. |
| [12] | XU T Y, WANG P, TIAN J S, et al. Pharmacological characterization of MT-1207, a novel multitarget antihypertensive agent[J]. Acta Pharmacol Sin, 2021, 42(6):885-897. doi: 10.1038/s41401-021-00636-1 |
| [13] | RAPSOMANIKI E, TIMMIS A, GEORGE J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people[J]. Lancet, 2014, 383(9932):1899-1911. doi: 10.1016/S0140-6736(14)60685-1 |
| [14] | QIU Y M, XU S Y, CHEN X, et al. NAD+ exhaustion by CD38 upregulation contributes to blood pressure elevation and vascular damage in hypertension[J]. Signal Transduct Target Ther, 2023, 8(1):353. doi: 10.1038/s41392-023-01577-3 |
| [15] | TIAN J S, WEI Y C, WANG P, et al. Pharmacological effects of MT-1207 in bilateral renal artery stenosis hypertension and its hypotensive targets validation[J]. Biomed Pharmacother, 2024, 178:117234. doi: 10.1016/j.biopha.2024.117234 |
| [16] | LING Q S, ZHANG S L, TIAN J S, et al. Allisartan isoproxil reduces mortality of stroke-prone rats and protects against cerebrovascular, cardiac, and aortic damage[J]. Acta Pharmacol Sin, 2021, 42(6):871-884. doi: 10.1038/s41401-021-00684-7 |
| [17] | WU M Y, MA X J, YANG C, et al. Effects of allisartan, a new AT(1)receptor blocker, on blood pressure and end-organ damage in hypertensive animals[J]. Acta Pharmacol Sin, 2009, 30(3):307-313. doi: 10.1038/aps.2009.11 |
| [18] | OTALI D, FREDENBURGH J, OELSCHLAGER D K, et al. A standard tissue as a control for histochemical and immunohistochemical staining[J]. Biotech Histochem, 2016, 91(5):309-326. doi: 10.1080/10520295.2016.1179342 |
| [19] | SHIMAMURA T, IWASAKI T, HAYASAKI-KAJIWARA Y, et al. Effects of losartan and benazepril on abnormal circadian blood pressure rhythm and target organ damage in SHRSP[J]. Clin Exp Hypertens, 2002, 24(3):187-205. doi: 10.1081/CEH-120003200 |
| [20] | SOMA M, LALM S K. The role of nicotinamide mononucleotide (NMN) in anti-aging, longevity, and its potential for treating chronic conditions[J]. Molecular Biology Reports, 2022, 49(10):9737-9748. doi: 10.1007/s11033-022-07459-1 |
| [21] | Yi L, Maier A B, Tao R, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial[J]. Geroscience, 2023, 45(1):29-43. doi: 10.1007/s11357-022-00705-1 |